International Residency

The Incubator

The front door
for international biotech in Australia

Jumar is a landing pad for international companies running clinical and R&D work in Australia.

More than lab space, Jumar’s unique physical environment and wraparound services are designed to provide early-stage and scaling biotech ventures with an integrated approach, supporting research translation from day one.

Australia is a fast, credible and cost-effective place to run early clinical work, with globally recognised trial data, government incentives that reward R&D investment, and a stable base for growth across the region.

At the centre of the Melbourne Biomedical Precinct

Jumar sits inside CSL's global headquarters, in one of the densest biomedical precincts in the Asia-Pacific. Leading clinical trial sites, hospitals, researchers and commercialisation service providers are in close proximity, alongside Jumar's mentor network and connections across the Cicada ecosystem.

A faster path to the clinic

Australia offers one of the quickest routes into early-phase trials, so first-in-human work can start sooner than in many other markets. Trials run to international standards and results that are recognised by major regulators, including the FDA and EMA.

Lower costs and R&D incentives

Australia is a cost-effective place to run early clinical work, and government incentives reward companies that invest in R&D here. Together they stretch early-stage budgets further, so teams can do more before raising again.

A base for growth across Asia-Pacific

Australia is a stable, well-regulated place to operate, with strong IP protections and the infrastructure to support early-stage work. For international teams it works as a credible base to build reach across the region from the start.